Movement Alert｜Eli Lilly Falls 3.03% in Regular Trading, Retreating from Record High Amid Broad Pharma Sector Weakness

Market Focus06-30 22:31

On June 30, Eli Lilly declined 3.03% in regular trading, trading at $1,191.36/share, with turnover of $794 million. The pullback follows the stock surging to an all-time high of $1,238 in the prior session, after rallying over 7% on the back of its leukemia drug Jaypirca receiving a positive recommendation from the EU CHMP for full-line CLL treatment.

The broader pharmaceutical sector traded uniformly weaker on the session, with Johnson & Johnson down 1.86%, Merck down 1.86%, Bristol-Myers Squibb down 2.05%, Pfizer down 1.50%, and Novo Nordisk down 0.87%. Eli Lilly's decline outpaced sector peers despite positive developments including a China distribution agreement with Innovent Biologics for breast cancer drug Verzenios and selection for an FDA pilot program aimed at accelerating new manufacturing facility approvals.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1107006064?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 22:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107006064","market":"us","top_or_hot":-1,"title":"Movement Alert｜Eli Lilly Falls 3.03% in Regular Trading, Retreating from Record High Amid Broad Pharma Sector Weakness","media":"Market Focus","content":"<p><p>On June 30, Eli Lilly declined 3.03% in regular trading, trading at $1,191.36/share, with turnover of $794 million. The pullback follows the stock surging to an all-time high of $1,238 in the prior session, after rallying over 7% on the back of its leukemia drug Jaypirca receiving a positive recommendation from the EU CHMP for full-line CLL treatment.</p><p>The broader pharmaceutical sector traded uniformly weaker on the session, with Johnson & Johnson down 1.86%, Merck down 1.86%, Bristol-Myers Squibb down 2.05%, Pfizer down 1.50%, and Novo Nordisk down 0.87%. Eli Lilly's decline outpaced sector peers despite positive developments including a China distribution agreement with Innovent Biologics for breast cancer drug Verzenios and selection for an FDA pilot program aimed at accelerating new manufacturing facility approvals.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Eli Lilly Falls 3.03% in Regular Trading, Retreating from Record High Amid Broad Pharma Sector Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Eli Lilly Falls 3.03% in Regular Trading, Retreating from Record High Amid Broad Pharma Sector Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-30 22:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 30, Eli Lilly declined 3.03% in regular trading, trading at $1,191.36/share, with turnover of $794 million. The pullback follows the stock surging to an all-time high of $1,238 in the prior session, after rallying over 7% on the back of its leukemia drug Jaypirca receiving a positive recommendation from the EU CHMP for full-line CLL treatment.</p><p>The broader pharmaceutical sector traded uniformly weaker on the session, with Johnson & Johnson down 1.86%, Merck down 1.86%, Bristol-Myers Squibb down 2.05%, Pfizer down 1.50%, and Novo Nordisk down 0.87%. Eli Lilly's decline outpaced sector peers despite positive developments including a China distribution agreement with Innovent Biologics for breast cancer drug Verzenios and selection for an FDA pilot program aimed at accelerating new manufacturing facility approvals.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"","article_id":"1107006064","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107006064","pubTimestamp":1782829869,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 30, Eli Lilly declined 3.03% in regular trading, trading at $1,191.36/share, with turnover of $794 million. The pullback follows the stock surging to an all-time high of $1,238 in the prior...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"动向提示|礼来公司常规交易下跌3.03%，在制药板块普遍疲软的情况下从历史高位回落","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"On June 30, Eli Lilly declined 3.03% in regular trading, trading at $1,191.36/share, with turnover of $794 million. The pullback follows the stock surging to an all-time high of $1,238 in the prior session, after rallying over 7% on the back of its leukemia drug Jaypirca receiving a positive recommendation from the EU CHMP for full-line CLL treatment.The broader pharmaceutical sector traded uniformly weaker on the session, with Johnson & Johnson down 1.86%, Merck down 1.86%, Bristol-Myers Squibb down 2.05%, Pfizer down 1.50%, and Novo Nordisk down 0.87%. Eli Lilly's decline outpaced sector peers despite positive developments including a China distribution agreement with Innovent Biologics for breast cancer drug Verzenios and selection for an FDA pilot program aimed at accelerating new manufacturing facility approvals.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107006064","isCrawlerRequest":true}